Cooperative Assessment of Late Effects for SCD Curative Therapies (COALESCE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05153967 |
|
Recruitment Status :
Recruiting
First Posted : December 10, 2021
Last Update Posted : August 26, 2022
|
Sponsor:
Vanderbilt University Medical Center
Collaborators:
Johns Hopkins University
Children's National Research Institute
Emory University
Information provided by (Responsible Party):
Michael DeBaun, Vanderbilt University Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with >99% of those born in high resource settings, including the United States, France, and England, now surviving to 18 years of age. However, the life expectancy of adults with SCD is severely shortened. Dysfunction of the heart, lung, and kidney is directly associated with decreased life expectancy. With the variety of curative therapies that are now available for SCD, long-term health outcomes studies are time-sensitive. As of now, efforts to determine long-term health outcomes following curative therapies for SCD have been limited. Though curative therapies initially should provide a cure for symptoms of SCD, there is the risk of late health outcomes to consider. Defining health outcomes following curative therapy is essential to improve personalized decision-making when considering curative versus disease-modifying therapeutic options. The primary goal of this study is to determine whether curative therapies for individuals with SCD will result in improved or worsening heart, lung, and kidney damage when compared to individuals with SCD receiving standard therapy. The investigators will also explore whether certain genes are associated with a good or bad outcome after curative therapy for SCD.
| Condition or disease |
|---|
| Sickle Cell Disease Pulmonary Disease Renal Disease Heart Disease |
Our primary objective is initiating a personalized approach to curative therapies in children and adults with sickle cell disease (SCD) to maximize benefits and limit adverse outcomes. Limited clinical studies exist to determine the long-term health outcomes following curative therapies for SCD. With emerging curative therapies for SCD (allogeneic [allo] hematopoietic stem cell transplant [HSCT], gene therapy/editing), long-term health outcomes studies are critical to inform personalized choices. Unfortunately, adverse outcomes have started to emerge after SCD curative therapy. Thus, risks of a cure in SCD must be measured against the benefits of a cure, including stabilization of lung function (FEV1) and improved tricuspid regurgitant jet velocity [TRJV]. Ultimately, the shortened lifespan of individuals with SCD, attributable to declining heart (elevated TRJV), lung (decreased FEV1), and kidney (decreased eGFR) function, for which curative therapies were designed to ameliorate, must be measured against favorable and unfavorable late outcomes. In our multicenter retrospective-prospective cohort, the investigators will test the following hypotheses: 1a): myeloablative curative therapies for children with SCD will result in progressive pulmonary and renal dysfunction when compared to children with SCD receiving standard therapy; 1b): nonmyeloablative HSCT for adults with SCD will result in no significant change in FEV1% predicted, but will lead to accelerated decline in eGFR when compared to adults receiving standard therapy; 2) nonmyeloablative HSCT for adults with SCD will be associated with a clinically significant improvement in TRJV following HSCT; and 3) in adults with SCD, proliferative and genotoxic stress uniformly related to nonmyeloablative allo-HSCT and myeloablative gene editing will lead to post-HSCT therapy-related myeloid neoplasm of recipient origin. The investigators will address these hypotheses with the following aims: 1) evaluate the incidence of pulmonary and renal function in 1a: children with SCD receiving myeloablative curative therapies; and 1b: adults with SCD receiving nonmyeloablative allo-HSCT, compared to a pre-existing cohort of children and adults with SCD; 2) determine whether there is a clinically significant improvement in TRJV in adults with SCD, at least half having TRJV > 2.5 m/s, following nonmyeloablative allo-HSCT, 3) evaluate the prevalence, incidence and evolution of Clonal hematopoiesis of indeterminate potential (CHIP) concerning therapy-related myeloid neoplasm development following non-myeloablative HSCT or myeloablative gene editing in adults and children with SCD, and 4) evaluate accuracy and gaps involved in collecting clinical health record data directly from patients and family members in comparison to clinical health record data collected by research coordinators.
| Study Type : | Observational |
| Estimated Enrollment : | 750 participants |
| Observational Model: | Cohort |
| Time Perspective: | Other |
| Official Title: | U01 Cooperative Assessment of Late Effects for Sickle Cell Disease Curative Therapies |
| Actual Study Start Date : | July 12, 2022 |
| Estimated Primary Completion Date : | December 2025 |
| Estimated Study Completion Date : | February 2026 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Sickle cell disease
| Group/Cohort |
|---|
|
Pediatric Myeloablative allo-HSCT
Participants ages 4 to 17 years old with SCD who underwent or are scheduled to undergo myeloablative allo-HSCT.
|
|
Pediatric Standard Disease-Modifying Therapy
Participants ages 4 to 17 years old with SCD who receive standard therapy.
|
|
Adult Non-Myeloablative allo-HSCT
Participants ages 18 to 65 years old with SCD who underwent or are scheduled to undergo non-myeloablative allo-HSCT.
|
|
Adult Standard Disease-Modifying Therapy
Participants ages 18 to 65 years old with SCD who receive standard therapy.
|
Primary Outcome Measures :
- Measurement of longitudinal change in FEV1 [ Time Frame: Through study completion, an average of four years ]Measurements of forced expiratory volume in 1 second (FEV1) based on the global lung index will be acquired from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. FEV1 will be reported in liters. (References: Eur Respir J. Volume 40 Issue 6: pages 1324-1343, 2012 June 27; Am J Hematol. Volume 93 Issue 3: pages 408-415, 2018 March).
- Percent predicted value of longitudinal change in FEV1 [ Time Frame: Through study completion, an average of four years ]Percent predicted of forced expiratory volume in 1 second (FEV1) based on the global lung index will be acquired from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. FEV1 will be reported in percentage. (References: Eur Respir J. Volume 40 Issue 6: pages 1324-1343, 2012 June 27; Am J Hematol. Volume 93 Issue 3: pages 408-415, 2018 March).
- Measurement of longitudinal change in FVC [ Time Frame: Through study completion, an average of four years ]Measurements of forced volume capacity (FVC) based on the global lung index will be acquired from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. FVC will be reported in liters. (References: Eur Respir J. Volume 40 Issue 6: pages 1324-1343, 2012 June 27; Am J Hematol. Volume 93 Issue 3: pages 408-415, 2018 March).
- Percent predicted value of longitudinal change in FVC [ Time Frame: Through study completion, an average of four years ]Percent predicted of forced volume capacity (FVC) on the global lung index will be acquired from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. FVC will be reported in percentage. (References: Eur Respir J. Volume 40 Issue 6: pages 1324-1343, 2012 June 27; Am J Hematol. Volume 93 Issue 3: pages 408-415, 2018 March).
- FEV1/FVC Ratio Percentage [ Time Frame: Through study completion, an average of four years ]Percentage of FEV1/FVC ratio based on the global lung index will be acquired from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. (References: Eur Respir J. Volume 40 Issue 6: pages 1324-1343, 2012 June 27; Am J Hematol. Volume 93 Issue 3: pages 408-415, 2018 March). FEV1/FVC will be reported in percentage.
- Longitudinal change in eGFR [ Time Frame: Through study completion, an average of four years ]
Estimated GFR (eGFR) as a determinant of kidney disease will be collected from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. The eGFR will be tested as a linear variable and using eGFR Categories according to the KDIGO 2012 Guidelines (Table 5 - Reference: Kidney Int Suppl. Volume 3 Issue 1: pages 19-62, 2013 Jan) as follows:
i.G1 >/ 90 mL/min/1.73m2 ii.G2 60 - 89 mL/min/1.73m2 iii.G3a 45 - 59 mL/min/1.73m2 iv.G3b 30 - 44 mL/min/1.73m2 v.G4 15 - 20 mL/min/1.73m2 vi.G5 < 15 mL/min/1.73m2 The standard technique of measured GFR will be used and reported in mL/min/1.73m2.
- Longitudinal change in albuminuria levels [ Time Frame: Through study completion, an average of four years ]Data pertaining to persistent albuminuria (defined as >/ 30 mg/g creatinine on 2 evaluations) associated with a more rapid decline in eGFR on longitudinal follow-up (Reference: Blood Adv. Volume 4 Issue 7: pages 1501-1511, 2020 Apr 14) will be tested. Results will be reported in mg/g.
- Longitudinal change in TRJV in adults with SCD treated with nonmyeloablative allo HSCT in adults [ Time Frame: Through study completion, an average of four years ]Improvement in TRJV in adults with SCD following HSCT will be acquired. Results will be reported in m/sec.
- Longitudinal change in SBP/DBP in adults with SCD treated with nonmyeloablative allo HSCT in adults [ Time Frame: Through study completion, an average of four years ]Measurements of Systolic blood pressure (SBP)/Diastolic blood pressure (DBP) in adults with SCD following HSCT will be acquired. Results will be reported as a ratio (SBP (mmHg)/DBP (mmHg)).
Biospecimen Retention: Samples With DNA
Blood samples for genetic testing to identify whether genes may predict health outcomes.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 4 Years to 65 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Participants will be patient volunteers from the sickle cell disease clinics and transplant centers of participating study sites.
Criteria
Inclusion Criteria
- Confirmed laboratory diagnosis of SCD
- Ability to give informed consent
- Ability to provide pre- and post-curative therapy data
- Treated with either one HSCT or with standard disease-modifying therapy
Exclusion Criteria
•History of non-compliance
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05153967
Contacts
| Contact: Leshana Saint Jean, PhD | 6158751992 | leshana.saint.jean@vumc.org | |
| Contact: Kristin Wuichet, PhD | 6159366098 | kristin.wuichet@vumc.org |
Locations
| United States, District of Columbia | |
| Children's National Medical Center | Not yet recruiting |
| Washington, District of Columbia, United States, 20010 | |
| Contact: Allistair Abraham, MD 202-476-6690 AAbraham@childrensnational.org | |
| United States, Georgia | |
| Emory University School of Medicine | Not yet recruiting |
| Atlanta, Georgia, United States, 30322 | |
| Contact: Vivien Sheehan, MD, PhD 404-727-7100 vivien.sheehan@emory.edu | |
| United States, Maryland | |
| Johns Hopkins Hospital | Not yet recruiting |
| Baltimore, Maryland, United States, 21287 | |
| Contact: Richard Jones, MD 667-312-2400 rjjones@jhmi.edu | |
| National Institutes of Health Clinical Center | Not yet recruiting |
| Bethesda, Maryland, United States, 20814 | |
| Contact: Courtney Fitzhugh, MD 301-402-6496 courtney.fitzhugh@nih.gov | |
| United States, Tennessee | |
| Vanderbilt University Medical Center | Recruiting |
| Nashville, Tennessee, United States, 37232-9000 | |
| Contact: Michael R. DeBaun, MD, MPH 615-875-3040 ext 5-3040 m.debaun@vumc.org | |
Sponsors and Collaborators
Vanderbilt University Medical Center
Johns Hopkins University
Children's National Research Institute
Emory University
Investigators
| Principal Investigator: | Michael R DeBaun, MD, MPH | Vanderbilt University Medical Center |
| Responsible Party: | Michael DeBaun, Professor of Pediatrics and Medicine, Vanderbilt University Medical Center |
| ClinicalTrials.gov Identifier: | NCT05153967 |
| Other Study ID Numbers: |
210806 |
| First Posted: | December 10, 2021 Key Record Dates |
| Last Update Posted: | August 26, 2022 |
| Last Verified: | August 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | This research study's sharing plan involves study data, publications, and outcomes. We will adhere to the NIH Public Access Policy (NOT-OD-08-033) and provide publications generated through funding by this project at the time the final, peer- reviewed papers are accepted for journal publication to the National Library of Medicine's PubMed Central, either through NIHMS (NIH Manuscript Submission) or through the Publisher. All applicable proposals, applications, and reports will include the PubMed Central number (PMCID) for all NIH-funded papers. All sequence data will be uploaded to database of Genotypes and Phenotype (dbGaP). |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Michael DeBaun, Vanderbilt University Medical Center:
|
Myeloablative Autologous Gene Editing Myeloablative Autologous Gene Therapy Myeloablative allo-HSCT Nonmyeloablative allo-HSCT Disease-Modifying Therapy |
Additional relevant MeSH terms:
|
Heart Diseases Anemia, Sickle Cell Cardiovascular Diseases Anemia, Hemolytic, Congenital Anemia, Hemolytic |
Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn |